Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting ...

Scientists have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine learning algorithms to accelerate drug ...

Prof. Stewart Cole, Chairman of the Board of iM4TB, said: “Long-acting injectable antiretroviral formulations have simplified, and radically improved HIV-AIDS treatment and we are confident that this ...

Access Pharmaceuticals, Inc. (OTCBB: ACCP), announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its ...

Credit: Getty Images. Following the development of hypotension during anesthesia, the administration of phenylephrine has been shown to raise systolic and mean blood pressure. The Food and Drug ...

In this interview, News-Medical speaks to Thanh T. Nguyen, a project manager at Innocore Pharmaceuticals, about the mechanisms behind long-acting injectables. Innocore Pharmaceuticals is a drug ...

Despite decades of R&D effort, almost all biopharmaceuticals remain well beyond the reach of oral formulation technology. Today, these medicines are usually administered in a healthcare setting rather ...

Several coronavirus disease 2019 (COVID-19) vaccines require multiple doses for long-lasting immunity. However, a new study published in the journal Biomacromolecules has developed a promising ...

Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties Under the agreement, Seal Rock Therapeutics is ...